{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T05:06:01Z","timestamp":1724475961032},"reference-count":52,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Follicular lymphoma (FL) has a long natural history and typically indolent behavior. In the present era, there are a plethora of prognostic factors combining clinical, biological, and genetic data to determine patient prognosis and help develop treatment strategies over the course of a patient's lifetime. The rapid pace of tumor-specific and clinical advances in FL has created a challenge in the prioritization and implementation of these factors into clinical practice. Developing a comprehensive understanding of existing prognostic markers in FL will help select optimal ways of utilization in the clinical setting and investigate opportunities to define and intervene upon risk at FL diagnosis and disease recurrence.<\/jats:p>","DOI":"10.1182\/hematology.2021000264","type":"journal-article","created":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T12:12:11Z","timestamp":1639138331000},"page":"313-319","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":5,"title":["Follicular lymphoma: is there an optimal way to define risk?"],"prefix":"10.1182","volume":"2021","author":[{"given":"Carla","family":"Casulo","sequence":"first","affiliation":[{"name":"University of Rochester, Rochester, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2021,12,10]]},"reference":[{"issue":"6","key":"2021121012070764800_hem2021000264C1","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3322\/caac.21357","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"22","key":"2021121012070764800_hem2021000264C2","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1182\/blood-2017-11-816298","article-title":"Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA\/FIL study","volume":"131","author":"Cottereau","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2021121012070764800_hem2021000264C3","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/S2352-3026(14)70008-0","article-title":"Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies","volume":"1","author":"Trotman","year":"2014","journal-title":"Lancet Haematol"},{"issue":"30","key":"2021121012070764800_hem2021000264C4","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1200\/JCO.2016.66.9440","article-title":"Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies","volume":"34","author":"Meignan","year":"2016","journal-title":"J Clin Oncol"},{"issue":"4","key":"2021121012070764800_hem2021000264C5","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1470-2045(18)30102-5","article-title":"A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts","volume":"19","author":"Huet","year":"2018","journal-title":"Lancet Oncol"},{"issue":"7","key":"2021121012070764800_hem2021000264C6","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1182\/bloodadvances.2017015164","article-title":"Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lymphoma","volume":"2","author":"Delfau-Larue","year":"2018","journal-title":"Blood Adv"},{"issue":"1","key":"2021121012070764800_hem2021000264C7","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1182\/blood-2018-99-117235","article-title":"Baseline PET-derived metabolic tumor volume metrics did not predict outcomes in follicular lymphoma patients treated with first-line immuno chemotherapy and antibody maintenance in the phase III GALLIUM study","volume":"132","author":"Barrington","year":"2018","journal-title":"Blood"},{"issue":"26","key":"2021121012070764800_hem2021000264C8","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1200\/JCO.2012.48.3990","article-title":"Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa\/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource","volume":"31","author":"Link","year":"2013","journal-title":"J Clin Oncol"},{"issue":"7","key":"2021121012070764800_hem2021000264C9","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-020-00340-z","article-title":"Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups","volume":"10","author":"Batlevi","year":"2020","journal-title":"Blood Cancer J"},{"issue":"5","key":"2021121012070764800_hem2021000264C10","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/bjh.15708","article-title":"Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era","volume":"184","author":"Rivas-Delgado","year":"2019","journal-title":"Br J Haematol"},{"issue":"2","key":"2021121012070764800_hem2021000264C11","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1365-2141.2011.08942.x","article-title":"Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times","volume":"156","author":"Wahlin","year":"2012","journal-title":"Br J Haematol"},{"issue":"3","key":"2021121012070764800_hem2021000264C12","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/ejh.13359","article-title":"Long-term outcome comparing histological grades of follicular lymphoma patients treated with immunochemotherapy as first-line therapy: a retrospective analysis from two institutions","volume":"104","author":"Mercadal","year":"2020","journal-title":"Eur J Haematol"},{"issue":"23","key":"2021121012070764800_hem2021000264C13","doi-asserted-by":"crossref","first-page":"6624","DOI":"10.1158\/1078-0432.CCR-13-1120","article-title":"A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP +131iodine\u2014tositumomab","volume":"19","author":"Press","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2021121012070764800_hem2021000264C14","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2017-11-816405","article-title":"A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy","volume":"132","author":"Bachy","year":"2018","journal-title":"Blood"},{"issue":"5","key":"2021121012070764800_hem2021000264C15","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"issue":"2","key":"2021121012070764800_hem2021000264C16","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/annonc\/mds429","article-title":"Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices","volume":"24","author":"Nooka","year":"2013","journal-title":"Ann Oncol"},{"issue":"5","key":"2021121012070764800_hem2021000264C17","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood-2006-01-013367","article-title":"The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome","volume":"108","author":"Buske","year":"2006","journal-title":"Blood"},{"issue":"3","key":"2021121012070764800_hem2021000264C18","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. Clinical trial randomized controlled trial","volume":"15","author":"Brice","year":"1997","journal-title":"J Clin Oncol"},{"issue":"12","key":"2021121012070764800_hem2021000264C19","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.7150\/jca.50552","article-title":"Prognostic value of peripheral blood lymphocyte\/monocyte ratio in lymphoma","volume":"12","author":"Gao","year":"2021","journal-title":"J Cancer"},{"issue":"9","key":"2021121012070764800_hem2021000264C20","doi-asserted-by":"crossref","first-page":"e606","DOI":"10.1016\/j.clml.2020.03.007","article-title":"Prognostic significance of absolute lymphocyte count, absolute monocyte count, and absolute lymphocyte count to absolute monocyte count ratio in follicular non-Hodgkin lymphoma","volume":"20","author":"Mohsen","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"2021121012070764800_hem2021000264C21","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1080\/10428194.2020.1821010","article-title":"A low lymphocyte-to-monocyte ratio is an independent predictor of poorer survival and higher risk of histological transformation in follicular lymphoma","volume":"62","author":"Mozas","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"15","key":"2021121012070764800_hem2021000264C22","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood.2019001091","article-title":"Baseline SUVmax did not predict histological transformation in follicular lymphoma in the phase 3 GALLIUM study","volume":"135","author":"Mir","year":"2020","journal-title":"Blood"},{"issue":"8","key":"2021121012070764800_hem2021000264C23","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.2967\/jnumed.119.227249","article-title":"Time to prepare for risk adaptation in lymphoma by standardizing measurement of metabolic tumor burden","volume":"60","author":"Barrington","year":"2019","journal-title":"J Nucl Med"},{"issue":"1","key":"2021121012070764800_hem2021000264C24","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1182\/blood-2018-07-865428","article-title":"Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016","volume":"133","author":"Qu","year":"2019","journal-title":"Blood"},{"issue":"34","key":"2021121012070764800_hem2021000264C25","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1200\/JCO.18.02365","article-title":"Progression of disease within 24 months in follicular lymphoma is associated with reduced intratumoral immune infiltration","volume":"37","author":"Tobin","year":"2019","journal-title":"J Clin Oncol"},{"issue":"21","key":"2021121012070764800_hem2021000264C26","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells","volume":"351","author":"Dave","year":"2004","journal-title":"N Engl J Med"},{"issue":"15","key":"2021121012070764800_hem2021000264C27","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1158\/1078-0432.CCR-14-3253","article-title":"The prognostic impact of CD163-positive macrophages in follicular lymphoma: a study from the BC cancer agency and the lymphoma study association","volume":"21","author":"Kridel","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2021121012070764800_hem2021000264C28","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1182\/blood-2015-03-630012","article-title":"Prognostic value of circulating Bcl-2\/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy","volume":"126","author":"Zohren","year":"2015","journal-title":"Blood"},{"issue":"5","key":"2021121012070764800_hem2021000264C29","doi-asserted-by":"crossref","first-page":"8765","DOI":"10.18632\/oncotarget.14448","article-title":"The prognostic value of clonal heterogeneity and quantitative assessment of plasma circulating clonal IG-VDJ sequences at diagnosis in patients with follicular lymphoma","volume":"8","author":"Sarkozy","year":"2017","journal-title":"Oncotarget"},{"issue":"12","key":"2021121012070764800_hem2021000264C30","doi-asserted-by":"crossref","first-page":"e1002197","DOI":"10.1371\/journal.pmed.1002197","article-title":"Histological transformation and progression in follicular lymphoma: a clonal evolution study","volume":"13","author":"Kridel","year":"2016","journal-title":"PLoS Med"},{"issue":"23","key":"2021121012070764800_hem2021000264C31","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national lymphocare study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"8","key":"2021121012070764800_hem2021000264C32","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1182\/blood-2016-05-717355","article-title":"Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy","volume":"128","author":"Jurinovic","year":"2016","journal-title":"Blood"},{"issue":"10","key":"2021121012070764800_hem2021000264C33","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1200\/JCO.2013.51.5866","article-title":"Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy","volume":"32","author":"Maurer","year":"2014","journal-title":"J Clin Oncol"},{"issue":"22","key":"2021121012070764800_hem2021000264C34","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1182\/blood.V114.22.2698.2698","article-title":"Risk factors for early transformation of follicular lymphoma (FL): report from the National LymphoCare Study (NLCS)","volume":"114","author":"Wagner-Johnston","year":"2009","journal-title":"Blood"},{"issue":"22","key":"2021121012070764800_hem2021000264C35","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1200\/JCO.2015.65.7163","article-title":"Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial","volume":"34","author":"Sarkozy","year":"2016","journal-title":"J Clin Oncol"},{"issue":"4","key":"2021121012070764800_hem2021000264C36","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/bjh.15149","article-title":"Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study","volume":"184","author":"Link","year":"2019","journal-title":"Br J Haematol"},{"issue":"27","key":"2021121012070764800_hem2021000264C37","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular Lymphoma International Prognostic Index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol"},{"issue":"8","key":"2021121012070764800_hem2021000264C38","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1182\/bloodadvances.2019001261","article-title":"Impact of bone marrow biopsy on response assessment in immunochemotherapy-treated lymphoma patients in GALLIUM and GOYA","volume":"4","author":"Rutherford","year":"2020","journal-title":"Blood Adv"},{"issue":"12","key":"2021121012070764800_hem2021000264C39","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/ajh.25973","article-title":"Follicular Lymphoma Evaluation Index (FLEX): a new clinical prognostic model that is superior to existing risk scores for predicting progression-free survival and early treatment failure after frontline immunochemotherapy","volume":"95","author":"Mir","year":"2020","journal-title":"Am J Hematol"},{"issue":"12","key":"2021121012070764800_hem2021000264C40","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1182\/bloodadvances.2020004051","article-title":"Intratumoral T cells have a differential impact on FDG-PET parameters in follicular lymphoma","volume":"5","author":"Nath","year":"2021","journal-title":"Blood Adv"},{"issue":"19","key":"2021121012070764800_hem2021000264C41","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1182\/blood.2020008119","article-title":"Treatment dependence of prognostic gene expression signatures in de novo follicular lymphoma","volume":"137","author":"Bolen","year":"2021","journal-title":"Blood"},{"issue":"9","key":"2021121012070764800_hem2021000264C42","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol"},{"issue":"1","key":"2021121012070764800_hem2021000264C43","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1182\/blood-2019-130208","article-title":"Evaluation of the m7-FLIPI in patients with follicular lymphoma treated within the gallium trial: EZH2 mutation status may be a predictive marker for differential efficacy of chemotherapy","volume":"134","author":"Jurinovi","year":"2019","journal-title":"Blood"},{"issue":"2","key":"2021121012070764800_hem2021000264C44","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/bjh.16159","article-title":"M7-FLIPI is not prognostic in follicular lymphoma patients with first-line rituximab chemo-free therapy","volume":"188","author":"Lockmer","year":"2020","journal-title":"Br J Haematol"},{"issue":"1","key":"2021121012070764800_hem2021000264C45","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2019-126233","article-title":"Intrafollicular CD4+ T-cells as an independent predictor of early clinical failure in newly diagnosed follicular lymphoma","volume":"134","author":"Mondello","year":"2019","journal-title":"Blood"},{"issue":"11","key":"2021121012070764800_hem2021000264C46","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/S1470-2045(18)30618-1","article-title":"Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial","volume":"19","author":"Trotman","year":"2018","journal-title":"Lancet Oncol"},{"issue":"suppl 1","key":"2021121012070764800_hem2021000264C47","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1182\/blood-2018-99-115930","article-title":"Minimal residual disease response at end of induction and during maintenance correlates with updated outcome in the phase III GALLIUM study of obinutuzumab- or rituximab-based immunochemotherapy in previously untreated follicular lymphoma patients","volume":"132","author":"Pott","year":"2018","journal-title":"Blood"},{"issue":"364","key":"2021121012070764800_hem2021000264C48","doi-asserted-by":"crossref","first-page":"364ra155","DOI":"10.1126\/scitranslmed.aai8545","article-title":"Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA","volume":"8","author":"Scherer","year":"2016","journal-title":"Sci Transl Med"},{"issue":"16","key":"2021121012070764800_hem2021000264C49","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1200\/JCO.2017.76.5198","article-title":"Diagnosis-to-treatment interval is an important clinical factor in newly diagnosed diffuse large B-cell lymphoma and has implication for bias in clinical trials","volume":"36","author":"Maurer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"2021121012070764800_hem2021000264C50","first-page":"4666","article-title":"A fully automated measurement of total metabolic tumor burden in diffuse large B-cell lymphoma and follicular lymphoma","volume":"34","author":"Skander","year":"2019","journal-title":"Blood"},{"issue":"2","key":"2021121012070764800_hem2021000264C51","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1200\/JCO.18.00400","article-title":"Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French US and cohorts","volume":"37","author":"Sarkozy","journal-title":"J Clin Oncol"},{"key":"2021121012070764800_hem2021000264C52","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.21.01234","article-title":"Response-adapted postinduction strategy in patients with advanced-stage follicular lymphoma: The FOLL12 Study","author":"Luminar","year":"2021","journal-title":"Journal of Clinical Oncology"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2021\/1\/313\/1851762\/313casulo.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2021\/1\/313\/1851762\/313casulo.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T12:12:41Z","timestamp":1639138361000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2021\/1\/313\/482944\/Follicular-lymphoma-is-there-an-optimal-way-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,10]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12,10]]},"published-print":{"date-parts":[[2021,12,10]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2021000264","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12,10]]},"published":{"date-parts":[[2021,12,10]]}}}